The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities.
Faraone SV.
Neurosci Biobehav Rev. 2018 Apr;87:255-270. doi: 10.1016/j.neubiorev.2018.02.001. Epub 2018 Feb 8.
The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs.
Kalant H.
CMAJ. 2001 Oct 2;165(7):917-28.
Psychosis with Methylphenidate or Amphetamine in Patients with ADHD.
Moran LV, Ongur D, Hsu J, Castro VM, Perlis RH, Schneeweiss S.
N Engl J Med. 2019 Mar 21;380(12):1128-1138. doi: 10.1056/NEJMoa1813751.
Bupropion for treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of placebo-controlled randomized clinical trials.
Bakouni H, Sharafi H, Bahremand A, Drouin S, Ziegler D, Bach P, Le Foll B, Schütz CG, Tardelli V, Ezard N, Siefried K, Jutras-Aswad D.
Drug Alcohol Depend. 2023 Dec 1;253:111018. doi: 10.1016/j.drugalcdep.2023.111018. Epub 2023 Nov 4.
Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults.
Castells X, Blanco-Silvente L, Cunill R.
Cochrane Database Syst Rev. 2018 Aug 9;8(8):CD007813. doi: 10.1002/14651858.CD007813.pub3.
Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents.
Gillies D, Leach MJ, Perez Algorta G.
Cochrane Database Syst Rev. 2023 Apr 14;4(4):CD007986. doi: 10.1002/14651858.CD007986.pub3.
Attention-Deficit/Hyperactivity Disorder Medications and Work Disability and Mental Health Outcomes.
Taipale H, Bergström J, Gèmes K, Tanskanen A, Ekselius L, Mittendorfer-Rutz E, Helgesson M.
JAMA Netw Open. 2024 Mar 4;7(3):e242859. doi: 10.1001/jamanetworkopen.2024.2859.
Binge Eating Disorder.
Guerdjikova AI, Mori N, Casuto LS, McElroy SL.
Psychiatr Clin North Am. 2017 Jun;40(2):255-266. doi: 10.1016/j.psc.2017.01.003. Epub 2017 Mar 6.
Global prevalence of cannabis and amphetamine/methamphetamine use among adolescents in 47 countries: a population-based study from WHO database.
Son Y, Hong S, Yim Y, Kim S, Lee H, Lee K, Kim HJ, Jo H, Park J, Oh J, Lee S, Lee H, Nehs CJ, Smith L, Yon DK, Kang J.
World J Pediatr. 2025 Mar;21(3):291-305. doi: 10.1007/s12519-025-00883-w. Epub 2025 Mar 20.
Use Motives of Patients with Amphetamine-Type Stimulants Use Disorder and Attention-Deficit/Hyperactivity Disorder.
Thurn D, Riedner A, Wolstein J.
Eur Addict Res. 2020;26(4-5):254-262. doi: 10.1159/000508871. Epub 2020 Jun 19.
